Today: 19 January 2026
Subscribe
Browse Category

Pharma News News 26 December 2025 - 6 January 2026

GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

London, January 6, 2026, 09:03 GMT — Regular session GSK plc shares rose nearly 1% in early London trade on Tuesday after the drugmaker said Japan had approved its bronchial asthma treatment Exdensur. Shares were up 0.96% at 1,838 pence by 0830 GMT. Sharecast The decision lands as investors weigh whether GSK’s next wave of respiratory launches can broaden growth…
6 January 2026
··
BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms

BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms

New York, January 5, 2026, 14:30 (EST) — Regular session BridgeBio Pharma shares slid 7.5% to $72.34 in afternoon trading on Monday after opening at $78.44 and touching $79.24 earlier in the session. The drop outpaced a roughly 2.2% decline in the SPDR S&P Biotech ETF, a broad gauge of U.S. biotech stocks. The move lands just ahead of a…
5 January 2026
····
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

NEW YORK, December 31, 2025, 14:52 ET — Regular session Cytokinetics, Incorporated shares rose 3.7% to $63.63 in afternoon trading on Wednesday, after touching $64.40 earlier in the session. The stock traded as low as $60.87, while the S&P 500 tracker and Nasdaq 100 fund were both down about 0.4% to 0.5%. The move matters because Cytokinetics is nearing its…
31 December 2025
····
Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

NEW YORK, December 31, 2025, 11:55 ET — Regular session Shares of Cogent Biosciences slid on Wednesday, paring losses from earlier in the session, after the biotech disclosed a key regulatory filing while investors digested a cluster of insider stock sales. The stock was down 2.5% at $36.19, after touching a low of $34.33. The move comes as Cogent shifts…
31 December 2025
····
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

NEW YORK, December 30, 2025, 02:05 PM ET — Regular session Zenas BioPharma Inc shares fell $2.02, or 5.2%, to $37.03 in afternoon trading on Tuesday, after ending the prior session at $39.05. The stock ranged from $36.94 to $40.50, with about 123,000 shares traded. The drop came as biotech stocks eased in thin year-end trading, with the Nasdaq Biotechnology…
30 December 2025
····
Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

NEW YORK, December 30, 2025, 11:14 ET — Regular session Merus N.V. shares were halted on Tuesday after Nasdaq said the final merger step in Denmark’s Genmab’s $97-a-share cash acquisition closed before the market open, leaving the stock set for suspension on Dec. 31. Merus last traded around $90 late Monday, about 7% below its prior close, according to market…
30 December 2025
···
Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

NEW YORK, December 29, 2025, 23:16 ET — Market closed Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead rare-disease program. The stock traded between $0.20 and $0.30, with about 241 million shares changing hands, according to the company’s…
30 December 2025
···
Pfizer stock holds near $25 as Wall Street waits for the next big catalyst

Pfizer stock holds near $25 as Wall Street waits for the next big catalyst

NEW YORK, December 28, 2025, 23:32 ET — Market closed. Pfizer Inc shares edged higher in the last U.S. session, closing Friday up 0.24% at $25.09. The stock traded between $24.92 and $25.11 on the day. Investing The modest move leaves Pfizer in the mid-$20s, as investors weigh whether the drugmaker can stabilize revenue after a December reset of expectations…
29 December 2025
····
Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

NEW YORK, Dec. 27, 2025, 12:57 p.m. ET — Market closed (weekend) Healthcare stocks are heading into the final trading days of 2025 with a rare mix of “defensive” support and headline-driven volatility—exactly the combination that can matter most when liquidity is thin and investors are rebalancing portfolios into year-end. U.S. stock markets are shut today, but Friday’s post-Christmas session…
27 December 2025
···
Merck (MRK) Stock Update: Weekend Wrap, Latest Headlines, Analyst Targets, and What to Watch Before Monday’s Open

Merck (MRK) Stock Update: Weekend Wrap, Latest Headlines, Analyst Targets, and What to Watch Before Monday’s Open

NEW YORK, Dec. 27, 2025, 11:25 a.m. ET — Market closed (weekend) Merck & Co., Inc. (NYSE: MRK) heads into the final days of 2025 with investors weighing a steady holiday-week climb in the shares against a familiar set of longer-term questions: how fast Merck can broaden growth beyond Keytruda, how policy and pricing shifts may reshape demand, and what…
27 December 2025
···
Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

As of 2:34 a.m. ET in New York on Saturday, December 27, 2025, U.S. stock markets are closed for the weekend.Merck & Co., Inc. (NYSE: MRK) was last quoted around $106.78, up about 0.33% versus its prior close, based on the latest available pricing feed. With year-end trading under way and liquidity often thinner around the holidays, Merck is heading…
27 December 2025
····
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

NEW YORK — Friday, December 26, 2025 (9:13 a.m. ET): U.S. stocks are heading into a thin, post‑Christmas trading day, with Wall Street set for a relatively muted open as investors digest a strong 2025 tape and look ahead to 2026 rate and earnings narratives. Reuters In that kind of tape, headline-driven biotech names can swing harder than usual—and ABIVAX…
26 December 2025
····
1 2 3 4 5 … 10

Stock Market Today

  • Smith + Nephew Acquires Integrity Orthopaedics to Expand Shoulder Repair Portfolio
    January 19, 2026, 2:22 PM EST. Smith + Nephew (SNN) has acquired US-based Integrity Orthopaedics for $225 million upfront plus $225 million in milestone payments. This move strengthens SNN's Sports Medicine portfolio through the Tendon Seam system, a next-generation rotator cuff repair technology aimed at reducing high re-tear rates common in shoulder repair. The deal supports SNN's strategy of innovation and expands its addressable market in the $875 million US rotator cuff repair segment. Shares remained flat post-announcement but SNN's stock has gained 8% over six months versus a 7.1% industry decline. The acquisition is expected to enhance margins by 2028 and drive sustainable growth with integration into the existing shoulder product suite.
Go toTop